What COYOTE does

Coyote Bioscience (卡尤迪生物) is a Beijing-headquartered molecular diagnostics company founded in 2009 that develops and commercializes point-of-care testing (POCT) platforms for nucleic acid detection. Its core product family, FlashDetect, includes the Nano (portable single-sample system with voice-guided operation), Flash10 (mid-throughput 4-channel system), Flash20 (rapid 30-minute qPCR), and Robo (high-throughput robotic system processing up to 2,300 samples per 24 hours), all built around proprietary Molecular Parallel Reaction technology that compresses detection time from hours to 8-30 minutes. A closed all-in-one microfluidic cartridge ('swab-in, result-out') architecture eliminates the need for a professional PCR laboratory and pairs with a reagent menu covering COVID-19, influenza A/B, RSV/MP, GBS screening, and pharmacogenomic tests (CYP2C19, MTHFR, SLCO1B1/ApoE).

The company operates a hybrid B2B model combining direct hospital sales in China with a 60+ country international distributor network, monetizing through instrument placements and recurring proprietary reagent/consumable sales. Manufacturing is based in Beijing, Yixing (Jiangsu), and Tianjin, with a US R&D subsidiary in Alameda/Mountain View, California. Coyote reports product deployment across 30+ Chinese provinces serving 2,000+ hospitals, 1.45 billion+ cumulative tests performed, and regulatory clearances including NMPA Class III, CE-IVDR, ANVISA, and ISO 13485. Strategic partnerships span Chinese CDC, Peking Union Medical College Hospital, the Gates Foundation (tuberculosis), and a December 2025 strategic cooperation with Pfizer for integrated rapid anti-infection diagnosis-treatment models.

Name

COYOTE

Legal name

Coyote Bioscience Co., Ltd. (北京卡尤迪生物科技股份有限公司)

Website

https://coyotebio.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Coyote Bioscience is a Beijing-based molecular diagnostics company (founded 2009) that develops the FlashDetect family of POCT nucleic acid platforms — instruments paired with closed-cartridge reagent kits — serving hospitals, CDCs, customs, and pharmaceutical partners across 65+ countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

akta.pro secondary industries

Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK)

Keywords

• Molecular diagnostic instruments
• Point-of-care testing
• Nucleic acid detection
• Infectious disease diagnostics
• PCR reagent kits

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Molecular Diagnostic Instruments: Sale of FlashDetect instrument family (Nano, Flash10, Flash20, Robo) to hospitals, laboratories, and healthcare facilities
2. Reagent and Consumable Sales: Recurring sales of proprietary reagent cartridges and test kits. Consumables include All-in-One cartridges for COVID, influenza, respiratory pathogens, GBS, tuberculosis, and other infectious disease tests
3. Testing Services: Coyote Clinical Laboratory provides molecular diagnostic testing services to patients and healthcare providers

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Coyote Bioscience designs, manufactures, and sells automated molecular Point-of-Care Testing (POCT) instruments under the FlashDetect™ brand combined with proprietary closed-cartridge reagent kits for rapid nucleic acid detection of infectious diseases, pharmacogenomics, and women's health applications. The company also operates third-party clinical testing laboratories and provides mobile molecular diagnostic solutions for field deployment.

Product overview

COYOTE (卡尤迪生物/Coyote Bioscience) is a molecular diagnostic POCT company founded in 2009, offering a comprehensive portfolio centered on the FlashDetect™ family of automated nucleic acid detection platforms. The core product line includes FlashDetect™ Nano (portable single-sample system), FlashDetect™ Flash10 (mid-throughput 4-channel POCT), FlashDetect™ Robo (high-throughput robotic system processing 2300+ samples/day), and FlashDetect™ Flash20 (rapid 30-min system). Supporting instruments include Mini8 Plus (portable qPCR) and Gentier 48E (automated PCR). The reagent portfolio covers COVID-19/flu combination tests, standalone COVID-19 kits, influenza A/B tests, RSV/MP dual tests, pharmacogenomics kits (CYP2C19, MTHFR, SLCO1B1/ApoE), and GBS detection. The ecosystem is unified by the Small Flash Cartridge (采检一体) closed cartridge format enabling 'swab-in, result-out' operation across platforms. COYOTE operates in 65+ countries with ISO 13485 certification and CE-IVD/NMPA/ANVISA registrations.

Differentiator

Problem solved

Functional benefit

Brands

• FlashDetect™ (闪测): The company's flagship molecular POCT brand, including FlashDetect Nano, FlashDetect Flash10, FlashDetect Robo, and FlashDetect Flash20 systems for rapid nucleic acid testing.
• FlashDetect™ Flash10 (闪测精灵)
• FlashDetect™ Flash20 (闪测)
• FlashDetect™ Nano (闪测Nano)
• FlashDetect™ Robo (闪测英雄)
• 小闪舱 (Xiaoshan Cang / All-in-One Cartridge)
• 闪测方舱 (FlashDetect Mobile Lab)
• Gentier 48E
• Mini8 Plus
• 微滴式数字PCR系统 (Droplet Digital PCR System)

Products and services

• FlashDetect Nano (闪测Nano)
• FlashDetect Flash10 (闪测Flash10)
• FlashDetect Robo (闪测Robo)
• FlashDetect Flash20 (闪测Flash20)
• Mini8 Plus

Quantifiable outcome

• Detection time reduced from 2+ hours to 8-30 minutes
• +5 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

13 partnerships are on record, tiered core and minor.

• PfizercoreStrategic or Co-development Partner · 1 December 2025Strategic cooperation to build an integrated rapid anti-infection diagnosis and treatment model. Focus on severe infection patients requiring rapid pathogen diagnosis. First product: combined test for common gram-negative bacteria and carbapenemase resistance genes (Carba-R), reducing traditional pathogen diagnosis from days to ~45 minutes.
• Beijing Tongren Hospital ENT Research Institute (北京市耳鼻咽喉科研究所)coreStrategic or Co-development Partner · 3 September 2022Collaboration on CST1 rapid gene detection technology for chronic sinusitis diagnosis. Combining Coyote's POCT technology with the institute's sinusitis research to develop point-of-care testing for precision treatment guidance.
• Central South University Clinical Pharmacology Research Institute (中南大学临床药理研究所)coreStrategic or Co-development Partner · 24 July 2021FlashDetect mobile lab donation for personalized medicine research. Long-term cooperation in pharmacogenomics and drug microbiome research. Joint research on individualized medicine withAcademician Zhou Honghao's team.
• Chinese CDC - National Key LaboratorycoreStrategic or Co-development PartnerExclusive technology licensing agreement for COVID-19 variant detection technology. Validation of variant detection kits at China CDC P3 laboratory against Delta, Alpha, Beta and other variants.
• Beijing Peking Union Medical College Hospital (北京协和医院)coreStrategic or Co-development PartnerJoint research on respiratory infection epidemiology and immunological insights. Contributed technology support for Frontiers publication on post-COVID respiratory pathogens. Collaboration on clinical validation of POCT technology.
• Harvard University - David Weitz LaboratoryminorStrategic or Co-development PartnerCollaboration on digital PCR platform development, resulting in creation of million-droplet digital PCR system
• Chinese Academy of SciencesminorStrategic or Co-development PartnerAcademic collaboration on synthetic biology and molecular biology research. Founder Li Xiang studied under Academician Ouyang Qi.
• Medical Research Team (Beijing Third Hospital - Lu Hongzhou)coreStrategic or Co-development PartnerClinical collaboration on respiratory disease diagnosis. Lu Hongzhou, President of Shenzhen Third Hospital, advocates for rapid POCT diagnostics as first priority in treating respiratory diseases.
• Beijing Chest Hospital (北京胸科医院)coreStrategic or Co-development PartnerJoint development of tongue swab tuberculosis molecular POCT testing solution. Non-invasive testing solution for patients unable to produce sputum. 2025 collaboration resulted in WHO recommendation for tongue swab specimens.
• China CDC - Wang Jianwei AcademiciancoreStrategic or Co-development PartnerGovernment science and technology major project cooperation. Participation in national key R&D programs on emerging infectious disease prevention and control.
• Gates FoundationminorStrategic or Co-development PartnerInternational collaboration on tuberculosis POCT solution. Promotion of tuberculosis diagnosis technology in global high-burden regions.
• Beijing University First Hospital (北京大学第一医院)coreStrategic or Co-development PartnerCollaboration on maternal and child health intelligent precision diagnosis innovation. Joint establishment of Beijing Key Laboratory for reproductive health.
• Mali CICM Laboratory (马里CICM实验室)minorStrategic or Co-development PartnerChina-Mali Emerging Infectious Disease Joint Laboratory cooperation. Donation of molecular POCT systems worth 1.2 million RMB. Technical training for local laboratory technicians.

Scale indicators11 records

Recent moves14 records

Expansion highlights6 records

Broad incumbents

• Autobio Diagnostics: Autobio is a leading Chinese IVD company with a portfolio spanning immunoassay, microbiology, and molecular diagnostics. As a broader Chinese IVD incumbent, it competes with Coyote on hospital procurement panels and reagent menu breadth.
• BGI Genomics: BGI Genomics operates a broad molecular diagnostics and sequencing portfolio including high-throughput nucleic acid testing platforms. It competes with Coyote in COVID-19 testing, NIPT, and infectious disease diagnostics — particularly in China and Belt-and-Road markets.
• Abbott (ID NOW): Abbott's ID NOW is a broad-incumbent rapid molecular POCT platform with global hospital penetration and an established respiratory pathogen menu. It represents the larger, diversified competitor against which Coyote's Nano and Flash10 compete for speed-sensitive hospital accounts.
• Roche (cobas Liat): Roche's cobas Liat is a compact, rapid PCR system for point-of-care use in hospitals and urgent care settings. As a global diagnostics incumbent, Roche competes with Coyote on rapid molecular respiratory and infectious disease testing in international hospital channels.

Direct peers

• DAAN Gene: DAAN Gene is a major Chinese molecular diagnostics company with strong hospital penetration in PCR-based infectious disease testing. It is one of Coyote's closest direct competitors in the domestic Chinese molecular POCT market.
• Cepheid (Danaher): Cepheid's GeneXpert system is the global benchmark for molecular POCT — fully automated, cartridge-based nucleic acid testing with a deep hospital menu and established FDA clearances. Coyote benchmarks its 94.6% concordance and competitive pricing directly against GeneXpert.
• BioFire (bioMérieux): BioFire's FilmArray panels are the leading multiplex syndromic molecular POCT platform used in hospital emergency and infectious disease workflows. It competes head-to-head with Coyote's respiratory pathogen and Flash10 multi-channel detection capability.
• Sansure Biotech: Sansure is a leading Chinese molecular diagnostics company with a broad nucleic acid testing menu including respiratory pathogens, HPV, and infectious disease kits. It directly competes with Coyote in the Chinese hospital IVD market and on international tenders.

Emerging players

• GenMark Diagnostics (Roche): GenMark's ePlex system delivers multiplex molecular POCT for respiratory and bloodstream infections. Acquired by Roche, it represents an emerging-to-incumbent molecular POCT platform directly comparable to Coyote's Flash10 multi-channel offering.
• Mesa Labs / EKF Diagnostics (molecular POC): EKF Diagnostics and similar emerging molecular POCT players target rapid point-of-care nucleic acid testing for decentralized clinical and outbreak-response use cases, overlapping with Coyote's FlashDetect Nano positioning in resource-limited settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COYOTE